About Us

Current position: Home About Us





Team members


Innovative drug research projects


Leading Talent

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) (hereinafter referred to as "Kelun-Biotech" or the "Company") is a biopharmaceutical company committed to the R&D, manufacturing and commercialization of innovative drugs. Since its incorporation in 2016, Kelun-Biotech has been committed to addressing medical needs in China and globally. Empowered by our integrated drug development capabilities and a well-established management systems that covers all key business functionalities, Kelun-Biotech is dedicated to the in-house development of differentiated treatments to improve the existing standard of medical care. As one of the pioneers and innovators in the development of antibody drug conjugates (ADCs), Kelun-Biotech has accumulated more than ten years of experience in ADC development and is one of the first biopharmaceutical companies in China, and one of the few globally, to establish an integrated ADC R&D platform, OptiDC.

 The Company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Over the years, the Company has developed integrated capabilities encompassing all key drug development functionalities, including research and development, manufacturing, quality control and commercialization. The Company’s capabilities empower us to rapidly and strategically advance a differentiated pipeline of over 30 assets, including over 10 in clinical stage. Supported by three in-house developed technology platforms, Kelun-Biotech has proprietary know-how in ADCs, biologics (monoclonal antibodies (mAbs) and bispecific antibodies (bsAbs)), as well as small molecule drugs. This approach has been validated by many of our clinical-stage drug candidates. The Company has built a strong pipeline with diversified and synergistic effects in terms of drug modalities, mechanisms and indication coverage.

 Kelun-Biotech is well-positioned to expand its commercialization infrastructure and market access by leveraging our controlling shareholder Kelun Pharmaceutical Group's decades-long experience, industry connections and extensive network. At the same time, the clinical value of Kelun-Biotech's pipeline and its drug development capabilities are recognized by the strategic partnerships worldwide. To date, the Company has entered into nine out-license agreements, including three license and collaboration agreements with Merck Sharp & Dohme LLC (together with its affiliates, “MSD”) to develop ADC assets for cancer treatment with upfront and milestone payments totaling up to US$10 billion. These strategic partnerships are not only testaments to our R&D and business development capabilities, but also are key drivers of our continued innovation, global influence and long-term growth.

Going forward, Kelun-Biotech strives to advance its pipeline towards commercialization and enhance its integrated drug development capabilities, and continues to lead the R&D and clinical activities of drug candidates. In addition, Kelun-Biotech is dedicated to optimizing its R&D platforms and developing novel technologies to support the R&D of innovative drugs. Kelun-Biotech will also continue to expand its cGMP manufacturing and quality control facilities, and enhance its in-house commercialization functionalities, to support the future launch of its pipeline assets and achieve its goal to become a leading global biopharmaceutical company.

Awards & Milestones

Leadership Team

Executive Team
Board of Directors

Mr. LIU Gexin

Chairman of the Board

Dr. GE Junyou



Chief Strategy Officer

Dr. ZHANG Yiwei

General Deputy Manager and Responsible for Manufacturing & Quality Control

Dr. TAN Xiangyang

Chief Scientific Officer

Dr. JIN Xiaoping

Chief Medical Officer

Mr. ZHOU Zejian

CFO, Secretary of the Board

Mr. GUO Yong

Chief Commercial Officer

Mr. LIU Gexin

Chairman of the Board and non-Executive Director

Dr. GE Junyou

General Manager, Executive Director

Mr. LIU Sichuan

Non-Executive Director

Mr. FENG Hao

Non-Executive Director

Mr. ZENG Xuebo

Non-Executive Director

Mr. LI Dongfang

Non-Executive Director

Dr. ZHENG Qiang

Independent Non-Executive Director

Dr. TU Wenwei

Independent Non-Executive Director

Dr. JIN Jinping

Independent Non-Executive Director

Dr. LI Yuedong

Independent Non-Executive Director


National Engineering Research Center Of Targeted Biologics
High-Tech Enterprise
2023 Global Unicorn Companies
Sichuan Innovation And Practice Base For Postdoctors